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Abstract. Neoadjuvant chemoradiotherapy is commonly used
to improve the local control and resectability of locally
advanced rectal cancer, with surgery performed after an
interval of a number of weeks. We have been conducting a
clinical trial of preoperative chemoradiotherapy in combination
with regional hyperthermia (hyperthermo-chemoradiation
therapy; HCRT) for locally advanced rectal cancer. In the
current study we assessed the effect of a longer (>10 weeks)
interval after neoadjuvant HCRT on pathological response,
oncological outcome and especially on apoptosis,
proliferation and p53 expression in patients with rectal
cancer. Forty-eight patients with proven rectal
adenocarcinoma who underwent HCRT followed by surgery
were identified for inclusion in this study. Patients were
divided into two groups according to the interval between
HCRT and surgery, ≤10 weeks (short-interval group) and >10
weeks (long-interval group). Patients in the long-interval
group had a significantly higher rate of pathological complete
response (pCR) (43.5% vs. 16.0%) than patients of the short-
interval group. Patients of the long-interval group had a
significantly higher rate of down-staging of T-stage (78.3%
vs. 36.0%) and relatively higher rate of that of N-stage
(52.2% vs. 36.0%) than patients of the short-interval group.
Furthermore, apoptosis in the long-interval group was
relatively higher compared to that of the short-interval group,
without a significant difference in the Ki-67 proliferative index
and expression of p53 in the primary tumor. In conclusion, we
demonstrated that a longer interval after HCRT (>10 weeks)
seemed to result in a better chance of a pCR, a result
confirmed by the trends in tumor response markers, including
apoptosis, proliferation and p53 expression.
Neoadjuvant chemoradiotherapy (CRT) is commonly used to
improve the local control and resectability of locally
advanced rectal cancer, with surgery performed after an
interval of several weeks (1-7). Current guidelines from the
National Comprehensive Cancer Network recommend that
patients with clinical stage II/III rectal cancer should be
treated with preoperative chemoradiation followed by total
mesorectal excision (TME) (8). We have been conducting a
clinical trial of preoperative chemoradiotherapy in
combination with regional hyperthermia (hyperthermo-
chemoradiation therapy; HCRT) for locally advanced rectal
cancer (9). The advantages of preoperative HCRT include
tumor down-staging, improved resectability and overall
survival, and increased anal sphincter preservation (9-11).
However, the optimal interval between CRT or HCRT and
surgery is still unclear.
In 1999, Francois et al. advocated the adoption of an
interval between chemoradiation and surgery of six to eight
weeks (12). Since the Lyon trial, this 6- to 8-week interval
has become part of the standard protocol for neoadjuvant
CRT of rectal cancer (7, 12). However, some studies recently
suggested that increased intervals could potentially increase
the tumor down-staging effect because radiation-induced
necrosis appears to be a time-dependent phenomenon (13). 
Therefore, in the current study we assessed the effect of a
long-term interval after neoadjuvant HCRT on pathological
response, oncological outcome and, worthy of special
mentioning, apoptosis, proliferation and p53 expression in
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patients with rectal cancer. The present study was designed
to determine whether an interval time between
chemoradiation and surgery of more than 10 weeks affects
tumor response because surgery was performed at a median
of 68 days after completion of HCRT interval in our
retrospective analysis.
Patients and Methods
Patients’ characteristics. Forty-eight patients with proven rectal
adenocarcinoma who underwent HCRT followed by surgery in the
Department of General Surgical Science, Graduate School of
Medicine, Gunma University, from April 2004 to December 2009
were identified for inclusion in this study. During the diagnostic
work-up, all patients underwent staging for distant metastasis and
lymph node metastasis with computed tomography (CT) of the
abdomen and thorax. T-Stage was determined by magnetic resonance
imaging (MRI) and colonoscopy with transrectal ultrasonography.
The staging work-up was repeated before surgery. The extent and
location of the tumor were classified according to the TNM.
Preoperative HCRT. All patients received preoperative HCRT. The
radiation treatment was delivered by 10-MV X-rays through a
three-field box technique. The clinical target volume encompassed
the primary tumor and the entire mesorectal tissue. The total
radiation dose was 50 Gy, with daily fractions of 2.0 Gy on five
consecutive days per week. Chemotherapy consisted of 5-FU (250
mg/m2 per day) and levofolinate calcium (25 mg/m2 per day)
administered by continuous infusion at night for five days a week
in the first, third, and fifth weeks of radiation. Two to five
hyperthermia sessions were performed once a week with 8-MHz
radiofrequency capacitive heating equipment (Thermotron-RF 8;
Yamamoto Vinita Co., Ltd., Japan). 
Surgical resection and postoperative follow-up. Rectal resection
was performed using the principles of TME with pelvic autonomic
nerve preservation eight weeks after the completion of HCRT but
because of logistics, scheduling, and other clinical factors, the
practical interval varied from five to 34 weeks and the median
interval was 68 days. The median interval obtained in cases with
incision was adopted as the cut-off value: 70 days (10 weeks): ≤10
weeks (short-interval group) and >10 weeks (long-interval group).
A complete 6-month course of adjuvant 5-FU-based chemotherapy
was typically recommended for all medically-fit patients
completing HCRT and curative surgery. The majority of patients
received oral 5-FU/leucovorin. All patients were closely followed-
up by surgeons. Postoperative follow-up on all patients was
conducted every three or six months for 2 years. After 2 years,
patients underwent follow-up examinations every six months. CT
of the abdomen and thorax was first done at the sixth postoperative
month and then yearly thereafter.
Pathology and immunohistochemistry. Histopathological examination
and evaluation of the pathological response to HCRT were performed
by experienced pathologists according to the histological criteria of
the Japanese Classification of Colorectal Carcinoma (14). Grades
were assigned according to the amount of necrosis, degeneration, and
lytic change of the tumor in the estimated total amount of the lesion
(15). Apoptosis of tumor cells was quantified by immuno-
histochemistry with M30-CytoDEATH antibody (Roche, Mannheim,
Germany). The cell cycle and apoptosis control gene p53 may play
a major role in the tumor response to cytotoxic agents such as
radiation and chemotherapy. Immunohistochemistry was performed
using formalin-fixed and paraffin-embedded tissue sections with the
following antibodies, according to the standard streptavidin-biotin
complex technique: anti-human M30-CytoDEATH (mouse
monoclonal, 1:6; Histofine) and anti-human p53 antibody. Antigen
retrieval was performed in an autoclave (citrate buffer, pH 6.0).
Isotype-matched non-immune IgG was used as a negative control
instead of the primary antibody, and showed negative results (data
not shown). Immunohistochemical staining for Ki-67 was performed
according to a previously described method (19, 20). Antigen
retrieval was performed in an autoclave (citrate buffer, pH 6.0). The
sections were incubated with anti-Ki-67 monoclonal antibody
(DAKO, Glostrup, Denmark) at a dilution of 1:100. The Ki-67
proliferative index (Ki index) was defined as the percentage of
nuclear-stained tumor cells among more than 1000 cells counted
(16, 17). Five high-power fields were evaluated for each of three
different regions. 
Statistical analysis. Patients were divided into two groups according
to the interval between HCRT and surgery, ≤10 weeks (short-
interval group) and >10 weeks (long-interval group). A univariate
analysis was conducted using Fisher’s exact test or the χ2 test with
or without Yates’ correction. To compare the two groups, Student’s
t-test was used. To test the independence of the risk factors, the
variables were entered into a multivariate logistic regression model
with a likelihood of p<0.05. The recurrence-free interval and overall
survival was calculated by the Kaplan–Meier method. The log-rank
test was used to evaluate differences between overall survival and
recurrence-free intervals. A value of p<0.05 was considered to be
statistically significant. 
Results
Patients’ and tumor characteristics. We analyzed the cases of
48 patients with rectal cancer who underwent HCRT followed
by rectal resection. The mean age of the patients was 61.4±9.4,
with an age distribution from 33-75 years, and 37 patients
(77.1%) were male. Patients’ characteristics are shown in
Table 1. All patients tolerated this regimen without
hematological toxicities. The practical interval from
completion of HCRT to surgery ranged from 5 to 34 weeks,
and the median time was 68 days. Out of the 48 patients, 25
(52.1%) underwent surgery less than 10 weeks after HCRT
completion (short-interval group), whereas 23 patients (47.9%)
underwent surgery 10 weeks or more after HCRT (long-
interval group). Table I summarizes not only the patient
characteristics, but also the results of the univariate analysis
conducted to determine the relationship between the short- and
long-interval groups. The two groups did not differ in age,
gender ratio, or distribution of clinical T-stage and N-stage.
Pathological and tumor response. When the clinical pre-
treatment stage was compared with the pathological results,
the overall down-staging rate, including both the T- and N-
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stage, was 72.9% (35 patients). Down-staging of the T- and
N-stages was possible in 27 (56.3%) and 21 patients
(43.8%), respectively. Patients of the long-interval group had
a significantly higher rate of down-staging of the T-stage
(36.0% vs. 78.3%) and a relatively higher rate of that of N-
stage (36.0% vs. 52.2%) than patients of the short-interval
group, respectively. Fourteen patients (29.2%) achieved
pathological complete response (pCR) of the primary tumor.
There was a significant difference in the pCR rate (short-
interval group: 16.0% vs. long-interval group; 43.5%;
p=0.037). No significant difference in the Ki-67 proliferative
index (Figure 1b) and expression of p53 (Figure 1c) of the
primary tumor was observed. Although the difference was
not statistically significant, the expression of M30-
CytoDEATH in the long-interval group tended to be higher
than that of the short-interval group (p=0.058) (Figure 1a). 
Oncological outcome. The median follow-up time from
surgery was 32 months (range=4 to 102 months). The local
recurrence rate was 6.3% (short 8.0% vs. long 4.3%;
p=0.532) and that for total metastasis was 25% (short 28.0%
vs. long 21.7%; p=0.435). The rates of local and distant
metastases were not significantly different between the two
groups. Disease-free survival and overall survival by
Kaplan–Meier curves differed between the two groups, but
the difference was not statistically significant (Figure 2). 
Discussion
Locally advanced rectal cancer is usually treated with
preoperative CRT followed by surgery. This strategy has
been shown to achieve pathological down-staging and
improve local control. We previously showed the advantage
of preoperative HCRT, or regional hyperthermia in
combination with CRT, for locally advanced rectal cancer,
including tumor down-staging, improved resectability and
overall survival, and increased anal sphincter preservation (9,
10). Although an interval of 6-8 weeks from CRT to surgery
is historically considered the standard, the optimal interval
has not yet been determined. The aim of this study was
therefore to assess the effect of a longer (>10 weeks) interval
after neoadjuvant HCRT on pathological response,
oncological outcome, and especially apoptosis, proliferation
and p53 expression in patients with rectal cancer.
The key observations made in this study can be
summarized as follows: i) Patients of the long-interval group
had significantly higher rate of pCR (43.5% vs. short interval
group 16.0%) than patients of the short-interval group; ii)
patients of the long-interval group had significantly higher
rate of T-staging than patients of the short-interval group,
respectively; and iii) apoptosis in the long-interval group
tend to be higher than that of the short-interval group without
significant difference in the Ki-67 proliferative index and
expression of p53 in primary tumor. These findings provide
clear evidence that a longer interval after HCRT (>10 weeks)
seems to result in a higher chance of a pCR, likely due the
tumor response, including effects on apoptosis, proliferation
and p53 expression.
The rate of pCR after preoperative CRT ranged from
10% to 16% in various series examined in a previous
review (18). Recently, some studies have demonstrated that
longer intervals between neoadjuvant CRT and surgery are
associated with favorable pathological findings (3, 19). In
a retrospective study, Tulchinsky et al. showed a longer
interval from preoperative CRT to surgery (>7 weeks) was
associated with higher rates of pCR or near-pCR than a
shorter interval (≤7 weeks) (35% vs. 17%) (20). Several
studies also reported that an extended time interval of
more than eight weeks between the end of preoperative
therapy and surgery led to a higher pCR rate (7). Some
studies have also shown that an interval longer than 10
weeks between completion of CRT and surgery is more
effective (7, 19). In the present study, the pCR rate of
patients with longer interval to surgery (>10 weeks) was
significantly higher than that of patients with a short
interval (43.5% vs. 16.0%), which compares favorably with
findings in other reports. The favorable results of our
current study might be due to additional HCRT. Further
investigations to improve the pCR rate of HCRT for rectal
cancer are required.
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Table I. Patients’ characteristics and clinicopathological features
associated with interval between HCRT and surgery. Values are
expressed as the mean±SD.
Short interval Long interval p-Value
(≤10 weeks) (>10 weeks)
N=25 N=23
Age (years) 63.0±8.6 59.7±10.2 0.228
Gender (male/female, n) 18/7 15/8 0.422
Preoperative T-stage (n) 
cT2 4 3 0.580
cT3 18 19
cT4 3 1
Preoperative N-positive (n) 14 13 0.601
Anal preserving surgery (n) 21 21 0.375
Adjuvant therapy (n) 17 9 0.031
pCR (n) 4 10 0.037
Down-staging T-stage (n) 9 18 0.004
Down-staging N-stage (n) 9 12 0.201
Ki-67 (%) 47.6±37.1 54.7±35.9 0.586
M30-CytoDEATH (%) 1.46±1.34 3.46±4.37 0.058
p53 (%) 47.4±37.1 34.4±36.8 0.353
Local recurrence (n) 2 1 0.532
Distant recurrence (n) 6 4 0.419
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Figure 1. Immunohistochemical finding of M30-cytoDEATH (a), Ki-67 (b) and p53 (c) after hyperthermochemoradiation therapy (H&E, ×200). No
significant difference in the Ki-67 proliferative index and expression of p53 in the primary tumor was observed. Although the difference was not
statistically significant, the expression of M30-CytoDEATH in the long-interval group tended to be higher than that of the short-interval group.
Figure 2. Time to tumor recurrence and overall survival by the Kaplan–Meier curves differ among patients of the longer- and the shorter-interval
groups, but no statistically significant differences were observed.
In addition, our study showed a significantly increased
rate of down-staging and relatively better oncological results
in patients of the long-interval group (>10 weeks). In our
previous study, down-staging was a good predictor of
oncological outcome (10), and several other studies have also
shown that pathological down-staging is an important
prognostic factor (4). These findings reflect the possibility
that a longer interval from HCRT to surgery is more effective
for oncological outcome. The fact that oncological outcomes
were not significantly different in the two groups in our
study might be due to the small sample size. Thus, further
investigations are needed in order to better document
oncological results.
Not all tumors respond to preoperative CRT. As the
interval to surgery increases, the tumor may in fact progress,
with detrimental effects on resectability; eventually, this
could negatively impact the oncological outcome (21). There
is no evidence-based protocol to follow if the tumor fails to
regress or increases in size after HCRT. Therefore, in the
current study, we assessed the effect of a longer-term interval
after neoadjuvant HCRT on tumor response, including
apoptosis, proliferation and p53 expression, in addition to
pathological response, or oncological outcome, in patients
with rectal cancer. In the current study, no significant
difference in the Ki-67 proliferative index and expression of
cell cycle and apoptosis control gene p53 in primary tumor
after a long interval (>10 weeks) from HCRT were observed
(Figure 1). The expression of M30-CytoDEATH, an
apoptotic gene, in the long-interval group tended to be higher
than that of the short-interval group, but the difference was
not statistically significant (Figure 1a). Tumor regression and
radiation-induced necrosis are a time-dependent phenomenon
(13). These data emphasize that a longer interval, beyond 10
weeks, is safe and tolerable from the viewpoint of tumor
behavior after HCRT. 
This study showed that a longer interval (>10 weeks)
was effective with a significantly higher pCR rate.
However, the important question regarding the optimal
timing from HCRT to surgery remains unanswered.
Furthermore, controversy exists about the surgical treatment
of patients with pCR, compared to more conservative
approaches such as a wait-and-see strategy (22). The
downside and danger is the potential effect of tumor
progression during this therapy-free interval. Major
challenges still remain with regard to the optimal timing for
surgery and patient selection for the conservative strategy.
Predictors of response to HCRT and implementation of
individualized strategies are necessary to extend the interval
between HCRT and surgery even more.
This study has potential limitations. It was a retrospective
analysis and the number of cases in our study was relatively
small. However, the results of our study are encouraging in
terms of the rate of pCR, down-staging, and tumor response
after HCRT. Further studies are required to determine
strategies for optimizing the oncological outcome on an
individual basis.
In conclusion, we have demonstrated that a longer interval
after HCRT (>10 weeks) resulted in a significant better
chance of a pCR, likely due to tumor response, including
apoptosis, proliferation and p53 expression. This study
showed the effectiveness and safety of a longer interval (>10
weeks) after HCRT; however, this interval should be
examined in the context of a randomized control trial. 
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